Foghorn Therapeutics Statistics
Share Statistics
Foghorn Therapeutics has 55.72M
shares outstanding. The number of shares has increased by 0.51%
in one year.
| Shares Outstanding | 55.72M |
| Shares Change (YoY) | 0.51% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 64.28% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 89 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 1.06M, so 1.91% of the outstanding
shares have been sold short.
| Short Interest | 1.06M |
| Short % of Shares Out | 1.91% |
| Short % of Float | 3% |
| Short Ratio (days to cover) | 10.43 |
Valuation Ratios
The PE ratio is -2.99 and the forward
PE ratio is -4.16.
Foghorn Therapeutics's PEG ratio is
0.09.
| PE Ratio | -2.99 |
| Forward PE | -4.16 |
| PS Ratio | 11.46 |
| Forward PS | 2.2 |
| PB Ratio | -5.69 |
| P/FCF Ratio | -2.56 |
| PEG Ratio | 0.09 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Foghorn Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.73,
with a Debt / Equity ratio of -0.82.
| Current Ratio | 3.73 |
| Quick Ratio | 3.73 |
| Debt / Equity | -0.82 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.37 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $201,803.57 |
| Profits Per Employee | $-773,392.86 |
| Employee Count | 112 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -22.22% in the
last 52 weeks. The beta is 3.13, so Foghorn Therapeutics's
price volatility has been higher than the market average.
| Beta | 3.13 |
| 52-Week Price Change | -22.22% |
| 50-Day Moving Average | 4.05 |
| 200-Day Moving Average | 6.07 |
| Relative Strength Index (RSI) | 54.09 |
| Average Volume (20 Days) | 139,598 |
Income Statement
In the last 12 months, Foghorn Therapeutics had revenue of 22.6M
and earned -86.62M
in profits. Earnings per share was -1.58.
| Revenue | 22.6M |
| Gross Profit | 19.48M |
| Operating Income | -102.68M |
| Net Income | -86.62M |
| EBITDA | -97.17M |
| EBIT | -100.28M |
| Earnings Per Share (EPS) | -1.58 |
Full Income StatementBalance Sheet
The company has 55.45M in cash and 37.13M in
debt, giving a net cash position of 18.32M.
| Cash & Cash Equivalents | 55.45M |
| Total Debt | 37.13M |
| Net Cash | 18.32M |
| Retained Earnings | -558.18M |
| Total Assets | 283.98M |
| Working Capital | 182.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -100.41M
and capital expenditures -906K, giving a free cash flow of -101.31M.
| Operating Cash Flow | -100.41M |
| Capital Expenditures | -906K |
| Free Cash Flow | -101.31M |
| FCF Per Share | -1.85 |
Full Cash Flow StatementMargins
Gross margin is 86.2%, with operating and profit margins of -454.31% and -383.24%.
| Gross Margin | 86.2% |
| Operating Margin | -454.31% |
| Pretax Margin | -383.24% |
| Profit Margin | -383.24% |
| EBITDA Margin | -429.9% |
| EBIT Margin | -454.31% |
| FCF Margin | -448.24% |
